---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-179243"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:41:05.082824+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda

## Summary
- Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.
- Adds Galafold (Fabry), Pombiliti+Opfolda (Pompe) and DMX-200 (FSGS) to commercial portfolio.
- Financed via $2.8B in new term loans ($2.0B Term B, $800M Term A) and 2034 notes.
- Expects to provide updated FY2026 guidance on May 4 earnings call.

## SEC filing metadata
- accession: 0001193125-26-179243
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/0001193125-26-179243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/d113922d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-179243
- JSON: https://secwatch.observer/filing/0001193125-26-179243.json
- Plain text: https://secwatch.observer/filing/0001193125-26-179243.txt

## Source-grounded claims
- claim_id: 51ac27a1a021604022e0e19e270ed16beaae932a
  claim: BIOMARIN PHARMACEUTICAL INC incurred credit facility of $2.0 billion senior secured term loan "B" facility, $800.0 million senior secured term loan "A" facility, and $600.0 mil with Citibank, N.A., as administrative agent and collateral agent at Term SOFR plus an applicable margin; for Term B Loans, 1.75% per annum for Term maturing Term Loan B Facility matures on seventh anniversary of Closing Date; Term Loan A Facility and Revolving Facility each mature on fifth anniversary of Closing Dat.
  evidence_excerpt: as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectively). The Credit Agreement provides for a $2.0 billion senior secured term loan “B” facility (the “ Term Loan B Facility ” and the loans thereunder, the “ Term B Loans ”), a $800.0 million senior secured term loan “A” facility (the “
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/0001193125-26-179243-index.htm
- claim_id: 1f0f9e55c48e70898ec966a7b162f8a336770a29
  claim: BIOMARIN PHARMACEUTICAL INC entered into Merger Agreement with Amicus valued at Amicus merged with and into Merger Sub with Amicus continuing as the surviving corporation and as a (effective 2026-04-27).
  evidence_excerpt: ursuant to the terms of the Merger Agreement, Amicus merged with and into Merger Sub (the “ Merger ”) with Amicus continuing as the surviving corporation and as a wholly owned subsidiary of BioMarin.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/0001193125-26-179243-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.